|
|
Blood, 15 March 2007, Vol. 109, No. 6, pp. 2604-2606.
Prepublished online as a Blood First Edition Paper on November 30, 2006; DOI 10.1182/blood-2006-09-046409.
 Previous Article | Next Article 
Submitted September 12, 2006
Accepted November 6, 2006
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study
Asher A Chanan-Khan*, Jonathan L. Kaufman, Jayesh Mehta, Paul G. Richardson, Kena C. Miller, Sagar Lonial, Nikhil C. Munshi, Robert Schlossman, Joseph Tariman, and Seema Singhal
Roswell Park Cancer Institute, Buffalo, NY
Emory University School of Medicine, Atlanta, GA
Northwestern University, Evanston, IL
Dana Farber Cancer Institute, Boston, MA
* Corresponding author; email: asher.chanan-khan{at}roswellpark.org.
Patients with multiple myeloma (MM) frequently present with concomitant renal dysfunction, and those requiring dialysis have particularly poor outcomes. Bortezomib is a reversible proteasome inhibitor with significant activity in MM. This retrospective case analysis evaluated the feasibility and activity of bortezomib-based therapy in MM patients (N = 24) requiring dialysis support for advanced renal failure. All but 1 patient were undergoing dialysis at the time of therapy. Patients received bortezomib alone or bortezomib-based combination therapy. Among 20 patients with available response data, overall response rate (complete response [CR] + partial response) was 75%, with 30% CR + near CR. One patient was spared dialysis, and 3 other patients became independent of dialysis following bortezomib-based treatment. These encouraging results suggest that bortezomib or bortezomib-based regimens can be used in MM patients requiring dialysis, with manageable toxicities. Further studies will more formally evaluate the impact of bortezomib-based regimens in this patient population.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. San-Miguel, J.-L. Harousseau, D. Joshua, and K. C. Anderson
Individualizing Treatment of Patients With Myeloma in the Era of Novel Agents
J. Clin. Oncol.,
June 1, 2008;
26(16):
2761 - 2766.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sitia, G. Palladini, and G. Merlini
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Haematologica,
October 1, 2007;
92(10):
1302 - 1307.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al.
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone
Haematologica,
October 1, 2007;
92(10):
1351 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ludwig, J. Drach, H. Graf, A. Lang, and J. G. Meran
Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma
Haematologica,
October 1, 2007;
92(10):
1411 - 1414.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Manochakian, K. C. Miller, and A. A. Chanan-Khan
Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma
Oncologist,
August 1, 2007;
12(8):
978 - 990.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson
New Drugs for Myeloma
Oncologist,
June 1, 2007;
12(6):
664 - 689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Richardson, C. Mitsiades, R. Schlossman, I. Ghobrial, T. Hideshima, D. Chauhan, N. Munshi, and K. Anderson
The Treatment of Relapsed and Refractory Multiple Myeloma
Hematology,
January 1, 2007;
2007(1):
317 - 323.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
